SquamousCellCarcinomaofSkin near Fishkill, NY

Biography: Meghna S. Trivedi, MD, MS cares for patients diagnosed with breast cancer. Dr. Trivedi received her medical degree from the University of Maryland School of Medicine, and completed her residency at the University of Pennsylvania. She went on to complete her fellowship in hematology/oncology at Columbia University. Dr. Trivedi co-leads the Hereditary Breast and Ovarian Cancer Program, a comprehensive, multi-disciplinary initiative aimed at screening, preventing, diagnosing, and treating hereditary breast and ovarian cancer. This innovative program brings together the resources of a world-renowned academic institution, including cutting-edge genomic testing, clinical trials, and experts in hereditary cancers across different specialties. Dr. Trivedi's research and care expertise also includes cancer genetics and genomics, precision medicine, and chemotherapy induced peripheral neuropathy. She is the principal investigator on several clinical trials, and has authored numerous publications in leading peer-reviewed journals. Dr. Trivedi is a member of the American Society of Clinical Oncologists and SWOG.

Biography: Originally from Columbus, OH, SunilIyercompleted his undergraduate studies at Washington University in St. Louis. He then completed his medical education and training at the University of Miami, where he served as chief hematology/oncology fellow. He has a strong interest in leukemia, particularly in the genomics and treatment of acute lymphoblastic leukemia.

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience We are devoted to providing services that are patient centered and compassionate and care for you as a person nbsp;

Biography: Benjamin Izar, MD, PhD is an assistant professor of medicine at the Columbia Vagelos College of Physicians and Surgeons in the division of Hematology/Oncology and a member of the Tumor Biology and Microenvironment Program at the Herbert Irving Comprehensive Cancer Center. Dr. Izar's clinical practice focuses on melanoma and cancer immunotherapy. In his lab, Dr. Izar studies interactions between cancer cells and cells of the tumor-microenvironment, and how these define metastatic niches, response and resistance to cancer immunotherapies. His lab develops and uses cutting-edge single-cell genomics and genome-editing tools to study patient tumors and models at unprecedented resolution Dr. Izar received his MD/PhD at Justus Liebig University in Giessen, Germany, where he was graduated summa cum laude. He completed his internal medicine residency training at Massachusetts General Hospital and medical oncology training at Beth Israel Deaconess Medical Center, followed by his first faculty position at Danna-Farber Cancer Institute. He completed post-doctoral research training in cancer immunology at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard. In addition to several awards he received during his training, Dr. Izar is the recipient of multiple national awards, including a NIH/NCI K08 Award (2017) and the prestigious Burroughs Welcome Fund Career Award for Medical Scientists (2018), and he was selected as a NextGen Star of the American Association for Cancer Research (2019). In 2020, he was selected as a Louis V. Gerstner, Jr. Scholar and a Velocity Fellow by Columbia University Vagelos College of Physicians and Surgeons. Dr. Izar is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, the Society for Immunotherapy of Cancer, and the Society for Melanoma Research.

Biography: Dr. Lentzsch is a Professor of Clinical Medicine and the Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York. She is at New York Presbyterian Hospital/ Columbia University Medical Center. After receiving her degrees from the Humboldt University/ Charit Berlin, Germany, she completed her residency and fellowship at Humboldt University. She did a research fellowship, studying the mechanism of action of thalidomide and its derivatives in multiple myeloma, in the Jerome Lipper Multiple Myeloma Center under the mentorship of Dr Kenneth Anderson at the Dana-Farber Cancer Institute, Boston, MA, USA. Dr. Lentzsch was recruited in August 2004 to the University of Pittsburgh and University of Pittsburgh Cancer Institute (UPCI), PA, USA, and served as Clinical Director of the Multiple Myeloma Program at UPCI before accepting the position as Director of the Multiple Myeloma and Amyloidosis Program at Columbia University Medical Center. She cares primarily for patients with plasma cell dyscrasia including MGUS, Multiple Myeloma, Amyloidosis, POEMS and Waldenstrom's Macroglobulinemia. Dr. Lentzsch is an internationally recognized expert in the field of Multiple Myeloma and Amyloidosis. She serves as a SWOG Myeloma Committee Member, SWOG Study Coordinator and International Myeloma Foundation "Black Swan Research Initiative" committee member. She is a member of the standing advisory board for the evaluation of Secondary Primary Malignancies associated with IMiDs.

Biography: Dr. Henick is a medical oncologist specializing in the care of patients with malignancies of the aerodigestive tract.As the Associate Director of Experimental Therapeutics and Director of Translational Research in Aerodigestive Cancers in Medical Oncology, Dr. Henick's clinical care and research are aligned to improve the effectiveness of, and limit toxicity from, emerging cancer treatments. These effortsentail clinical trials that Dr. Henick has written and leads to study novel therapeutic approaches and to reduce steroid dependence among patients experiencing adverse events fromimmunotherapy.

Biography: Dr. Ryan Moy is an Assistant Professor of Medicine and medical oncologist at Columbia University Irving Medical Center where he specializes in the treatment of gastrointestinal malignancies, with a focus on esophageal and stomach cancers. He received his MD/PhD from the University of Pennsylvania and completed internship and residency training in Internal Medicine at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. He then completed fellowship training in Medical Oncology at Memorial Sloan Kettering Cancer Center and postdoctoral research at The Rockefeller University. Dr. Moy is actively involved in translational research to understand the biological mechanisms that regulate metastasis, the primary driver of mortality in gastrointestinal cancers. He has performed laboratory-based research to define critical genes that promote liver metastasis in colorectal cancer. He is also conducting research to discover key vulnerabilities in esophageal and gastric cancers, with the goal of translating these findings from the lab to develop more effective treatments for patients. As an active member of the gastrointestinal oncology and experimental therapeutics groups, Dr. Moy is involved in developing and leading clinical trials investigating novel targeted and immunotherapy treatments for esophagogastric cancer and other malignancies. His work has been recognized by several awards including a Damon Runyon Cancer Research Foundation Fellow Award and a National Cancer Institute (NCI) K08 Career Development Award. Dr. Moy works as part of a multidisciplinary team with the mission of delivering compassionate and state-of-the-art oncologic care to each patient, using a precision medicine approach to provide innovative and promising treatments.

Biography: Dr. Yoanna Pumpalova is an Assistant Professor of Medicine and medical oncologist at Columbia University Irving Medical Center where she specializes in the treatment of gastrointestinal malignancies, with a focus on colorectal and anal cancers. She received her MD from Weill Cornell Medical College and completed internship and residency training in Internal Medicine and Global Health at Stanford University. She then completed fellowship training in Medical Oncology at Columbia University/New York Presbyterian Hospital. Dr. Pumpalova works as part of a multidisciplinary team with the mission of delivering compassionate and state-of-the-art oncologic care to each patient, using a precision medicine approach to provide innovative and promising treatments. Dr. Pumpalova is actively involved in translational research to understand the biological mechanisms driving early onset colorectal cancer. She collaborates with Dr. Joel Gabre, a gastroenterologist and clinician scientist and Dr. Beatrice Dionigi, colorectal surgeon, on research to understand how early onset colorectal cancer differs from average onset colorectal cancer, with the goal of uncovering novel ways to treat all patients with colorectal cancer. Dr. Pumpalova is also the site principal investigator of industry-sponsored clinical trials investigating novel therapies for the treatment of colorectal cancer. Further, Dr. Pumpalova conducts studies in low- and middle-income countries focused on early detection and screening for colorectal cancer. She has active studies in South Africa and Dominican Republic. Her research goal is to improve outcomes for patients diagnosed with colorectal cancer, regardless of where they reside. Her work has been recognized by several awards including an ASCO Young Investigator Award and ASCO Career Development Award. In the NewsColumbia Researchers Seek Answers for Rise of Colon Cancer in Younger PatientsWhat to Know About the Rise of Colorectal Cancer in Younger PeopleExploring Strategies for Earlier Colon Cancer Detection in Sub-Saharan Africa

Biography: Dr. Juan-Manuel Schvartzman, MD is an Oncology Specialist who practices in New York, NY. He is 46 years old and has been practicing for 23 years. Dr. Juan-Manuel Schvartzman, MD is affiliated with Newyork-Presbyterian.